Next Article in Journal
Psychosocial Care for Cancer: A Framework to Guide Practice, and Actionable Recommendations for Ontario
Previous Article in Journal
Outcomes of Women with Early-Stage Breast Cancer Receiving Adjuvant Trastuzumab
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 4
10.3747/co.19.972
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents

by
P. Larochelle
1,*,
C. Kollmannsberger
2,
R.D. Feldman
3,
E.L. Schiffrin
4,
L. Poirier
5,
F. Patenaude
4,
D. Ruether
6,
M. Myers
7 and
G. Bjarnason
7
1
Institut de recherches cliniques de Montréal, Montreal, QC, Canada
2
BC Cancer Agency–Vancouver, Vancouver, BC, Canada
3
Robarts Research Institute, London, ON, Canada
4
Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada
5
Hypertension Unit and Pharmacy Department, Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada
6
Tom Baker Cancer Centre, Calgary, AB, Canada
7
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(4), 202-208; https://doi.org/10.3747/co.19.972
Submission received: 3 May 2012 / Revised: 6 June 2012 / Accepted: 9 July 2012 / Published: 1 August 2012

Abstract

Inhibitors of the vascular endothelial growth factor (vegf-is) signalling pathway have fundamentally changed the treatment of metastatic renal cell carcinoma (mrcc). Hypertension is one of the most common side effects of vegf-is and has been reported with almost every vegf-i used for treatment to date. The exact mechanism of vegf-i–induced hypertension appears complex and multifactorial, and it remains to be fully explained. No randomized clinical trials are available to guide the management of hypertension during vegf-i treatment in mrcc patients. The guiding principles suggested here summarize the consensus of opinions on the diagnosis and management of vegf-i–induced hypertension during treatment of mrcc obtained from an expert working group composed of 4 Canadian medical oncologists and 5 Canadian hypertension specialists. The Canadian Hypertension Education Program guidelines, available literature, and expert opinion were used to develop the guiding principles.
Keywords: vascular endothelial growth factor inhibitors; hypertension; metastatic renal cell carcinoma vascular endothelial growth factor inhibitors; hypertension; metastatic renal cell carcinoma

Share and Cite

MDPI and ACS Style

Larochelle, P.; Kollmannsberger, C.; Feldman, R.D.; Schiffrin, E.L.; Poirier, L.; Patenaude, F.; Ruether, D.; Myers, M.; Bjarnason, G. Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents. Curr. Oncol. 2012, 19, 202-208. https://doi.org/10.3747/co.19.972

AMA Style

Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, Ruether D, Myers M, Bjarnason G. Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents. Current Oncology. 2012; 19(4):202-208. https://doi.org/10.3747/co.19.972

Chicago/Turabian Style

Larochelle, P., C. Kollmannsberger, R.D. Feldman, E.L. Schiffrin, L. Poirier, F. Patenaude, D. Ruether, M. Myers, and G. Bjarnason. 2012. "Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents" Current Oncology 19, no. 4: 202-208. https://doi.org/10.3747/co.19.972

APA Style

Larochelle, P., Kollmannsberger, C., Feldman, R. D., Schiffrin, E. L., Poirier, L., Patenaude, F., Ruether, D., Myers, M., & Bjarnason, G. (2012). Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents. Current Oncology, 19(4), 202-208. https://doi.org/10.3747/co.19.972

Article Metrics

Back to TopTop